Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of three systematic review(s)/meta-analysis(es). ^[1-3]
• Bexagliflozin demonstrated non-inferiority in reducing major adverse cardiovascular events (MACE+), with a hazard ratio (HR) of 0.80 (95% CI 0.58, 1.09), and for MACE with an HR of 0.82 (95% CI 0.59, 1.13).
• In glycemic control, bexagliflozin significantly reduced HbA1c by -0.45 (95% CI -0.55 to -0.34), fasting plasma glucose (FPG) by -1.37 (95% CI -1.73 to -1.00), body weight by -1.77 kg (95% CI -2.44 to -1.10), and systolic blood pressure by -4.11 mmHg (95% CI -6.18 to -2.03).
• Bexagliflozin showed a renal protective effect with a reduction in eGFR of -3.48 (95% CI -6.57 to -0.39), comparable to other SGLT2 inhibitors such as dapagliflozin and luseogliflozin.
• Bexagliflozin did not increase the risk of major adverse cardiovascular events (MACE) in participants with type 2 diabetes mellitus (T2DM), with safety outcomes consistent with the placebo arm.
• Renal safety outcomes indicated a reduction in eGFR, similar to other SGLT2 inhibitors like luseogliflozin and dapagliflozin, without a significant increase in adverse renal events.
• The studies focused on participants with type 2 diabetes mellitus (T2DM) and chronic kidney disease, with no significant differences in effectiveness or safety among various population types or subgroups explicitly reported in the provided documents.